AR

Arlan Rakhmetzhanov

18, founder @ nozomio (yc s25), research @ stanford, forbes 30u30, high school junior dropout

San Francisco, California

Work Experience

2025

  • Founder & CEO

    2025

    applied product lab. heads down building nia backed by CRV, YC, Paul Graham, BoxGroup, first investors in cursor, LocalGlobe, and more.

2024 - 2025

  • Research Assistant

    2024 - 2025

    Venture Capital Initiative. Work a lot with python and vc firms. A lot.

2025 - 2025

  • EF S25

    2025 - 2025

    dropped out, cool office though

2024 - 2025

  • Co-Founder

    2024 - 2025

    Part of LaunchX's summer batch at UC Berkeley Built a networking database designed to support young founders by facilitating connections, collaborations, and access to free learning resources.

2024 - 2024

  • Founder

    2024 - 2024

    my high school invested in my own startup 20K+ users (Extracurrify); 85K+ page visits (Extracurrify); 7,000+ iOS app downloads (Extracurrify); Ranked #10 in Kazakhstan's App Store (Education); Featured in DigitalBusiness KZ (>1M readers); Highlighted by @alga.kazakhstan (400K+ YouTube, 300K+ TikTok); 1.5M+ social media views; Partnered with 2 Palo Alto based startups

2023 - 2023

  • Software Engineer Intern

    2023 - 2023

    first experience at IPOed company worked on Optimus AI, a tool designed to identify and simplify the mining and copper extraction processes, as well as optimize plants for copper extraction. Trained their AI model, improved accuracy by 27%

2023 - 2023

  • Author

    2023 - 2023

    I am a self-published author on Amazon KDP, Google Books, and Rakuten Books. I released an introductory book about venture capital for youth and I want to expand and release new books in both VC and computer science fields in the future.

2022 - 2022

  • Junior Customer Service Manager

    2022 - 2022

    adapted PR strategies and content based on relevant media trends for the company's social networks with 570K+ followers and the main website, increasing user reach and engagement by 23%.